US9709703B2 - Ophthalmic lens material, ophthalmic lens, and method for making the same - Google Patents

Ophthalmic lens material, ophthalmic lens, and method for making the same Download PDF

Info

Publication number
US9709703B2
US9709703B2 US14/941,083 US201514941083A US9709703B2 US 9709703 B2 US9709703 B2 US 9709703B2 US 201514941083 A US201514941083 A US 201514941083A US 9709703 B2 US9709703 B2 US 9709703B2
Authority
US
United States
Prior art keywords
mixture
ophthalmic lens
hydrophilic monomer
total mass
mass percentage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
US14/941,083
Other versions
US20170123106A1 (en
Inventor
Hsiu-Wen Chien
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hon Hai Precision Industry Co Ltd
Original Assignee
Hon Hai Precision Industry Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hon Hai Precision Industry Co Ltd filed Critical Hon Hai Precision Industry Co Ltd
Assigned to HON HAI PRECISION INDUSTRY CO., LTD. reassignment HON HAI PRECISION INDUSTRY CO., LTD. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: CHIEN, HSIU-WEN
Priority to US15/429,187 priority Critical patent/US9804298B2/en
Publication of US20170123106A1 publication Critical patent/US20170123106A1/en
Application granted granted Critical
Publication of US9709703B2 publication Critical patent/US9709703B2/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G02—OPTICS
    • G02B—OPTICAL ELEMENTS, SYSTEMS OR APPARATUS
    • G02B1/00—Optical elements characterised by the material of which they are made; Optical coatings for optical elements
    • G02B1/04—Optical elements characterised by the material of which they are made; Optical coatings for optical elements made of organic materials, e.g. plastics
    • G02B1/041—Lenses
    • G02B1/043—Contact lenses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/38—Silver; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F220/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical or a salt, anhydride ester, amide, imide or nitrile thereof
    • C08F220/02—Monocarboxylic acids having less than ten carbon atoms; Derivatives thereof
    • C08F220/10—Esters
    • C08F220/20—Esters of polyhydric alcohols or phenols, e.g. 2-hydroxyethyl (meth)acrylate or glycerol mono-(meth)acrylate
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F220/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical or a salt, anhydride ester, amide, imide or nitrile thereof
    • C08F220/02—Monocarboxylic acids having less than ten carbon atoms; Derivatives thereof
    • C08F220/10—Esters
    • C08F220/26—Esters containing oxygen in addition to the carboxy oxygen
    • C08F220/28—Esters containing oxygen in addition to the carboxy oxygen containing no aromatic rings in the alcohol moiety
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F230/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and containing phosphorus, selenium, tellurium or a metal
    • C08F230/04—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and containing phosphorus, selenium, tellurium or a metal containing a metal
    • C08F230/08—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and containing phosphorus, selenium, tellurium or a metal containing a metal containing silicon
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G77/00—Macromolecular compounds obtained by reactions forming a linkage containing silicon with or without sulfur, nitrogen, oxygen or carbon in the main chain of the macromolecule
    • C08G77/48—Macromolecular compounds obtained by reactions forming a linkage containing silicon with or without sulfur, nitrogen, oxygen or carbon in the main chain of the macromolecule in which at least two but not all the silicon atoms are connected by linkages other than oxygen atoms
    • C08G77/50—Macromolecular compounds obtained by reactions forming a linkage containing silicon with or without sulfur, nitrogen, oxygen or carbon in the main chain of the macromolecule in which at least two but not all the silicon atoms are connected by linkages other than oxygen atoms by carbon linkages
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F220/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical or a salt, anhydride ester, amide, imide or nitrile thereof
    • C08F220/02—Monocarboxylic acids having less than ten carbon atoms; Derivatives thereof
    • C08F220/10—Esters
    • C08F220/26—Esters containing oxygen in addition to the carboxy oxygen
    • C08F220/28—Esters containing oxygen in addition to the carboxy oxygen containing no aromatic rings in the alcohol moiety
    • C08F220/281—Esters containing oxygen in addition to the carboxy oxygen containing no aromatic rings in the alcohol moiety and containing only one oxygen, e.g. furfuryl (meth)acrylate or 2-methoxyethyl (meth)acrylate
    • C08F2220/281—
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F230/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and containing phosphorus, selenium, tellurium or a metal
    • C08F230/04—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and containing phosphorus, selenium, tellurium or a metal containing a metal
    • C08F230/08—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and containing phosphorus, selenium, tellurium or a metal containing a metal containing silicon
    • C08F230/085—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and containing phosphorus, selenium, tellurium or a metal containing a metal containing silicon the monomer being a polymerisable silane, e.g. (meth)acryloyloxy trialkoxy silanes or vinyl trialkoxysilanes

Definitions

  • the subject matter herein generally relates to an ophthalmic lens, a method for making the ophthalmic lens, and an ophthalmic lens material for making the ophthalmic lens.
  • Contact lenses are commonly worn by users to correct vision, or for cosmetic or therapeutic reasons.
  • antibacterial agents are disposed on the surface of a contact lens, to prevent a user from suffering from eye damage such as acute red eye or microbial keratitis.
  • the FIGURE is a flowchart of an embodiment of a method for making an ophthalmic lens according to the present disclosure.
  • the FIGURE illustrates a flowchart of a method for making an ophthalmic lens in accordance with an exemplary embodiment.
  • the exemplary method is provided by way of example, as there are a variety of ways to carry out the method.
  • Each block shown in the FIGURE represents one or more processes, methods or subroutines, carried out in the exemplary method.
  • the illustrated order of blocks is by example only and the order of the blocks can change. Additional blocks may be added or fewer blocks may be utilized, without departing from this disclosure.
  • the exemplary method can begin at block 101 .
  • a mixture is formed by mixing dopamine methacrylamide, a hydrophilic monomer, a cross-linking agent, and a photoinitiator, wherein the dopamine methacrylamide has the chemical formula:
  • the dopamine methacrylamide has a mass percentage of about 0.5% to about 10% of a total mass of the mixture.
  • the hydrophilic monomer has a mass percentage of about 88.95% to about 99.494% of a total mass of the mixture.
  • the cross-linking agent has a mass percentage of about 0.001% to about 1% of a total mass of the mixture.
  • the photoinitiator has a mass percentage of about 0.005% to about 0.05% of a total mass of the mixture.
  • the hydrophilic monomer may be selected from a group consisting of methylacrylic acid compounds and acrylic compounds, or any combination thereof, such as 2-hydroxyethyl methacrylate (HEMA), methyl methacrylate (MMA), poly(dimethylsiloxane), 3-methacryloxypropyletris(trimethylsiloxy)silane, N-vinyl pyrrolidone (NVP), glycidyl methacrylate, N,N-dimethylacrylamide, and methyl acrylate (MA), or any combination thereof.
  • HEMA 2-hydroxyethyl methacrylate
  • MMA methyl methacrylate
  • NDP N-vinyl pyrrolidone
  • MA glycidyl methacrylate
  • the cross-linking agent may be selected from a group consisting of ethylene glycol dimethacrylate (EGDMA) and trimethylolpropane trimethacrylate (TMPTMA), or any combination thereof.
  • the photoinitiator may be available commercially from Chemical Industries Basel (CIBA) Corporation as a clear liquid under the trade name “Irgacure-1173”.
  • the mixture is fed into a mold and is exposed to ultraviolet radiation, to cause the dopamine methacrylamide, the hydrophilic monomer, the photoinitiator, and the cross-linking agent in the mixture to undergo a polymerization reaction, thereby forming the ophthalmic lens.
  • a time period for the ultraviolet irradiation is from about 10 min to about 30 min.
  • the ophthalmic lens is immersed in an antibacterial solution containing an antibacterial agent for a preset period of time, allowing the antibacterial agent to be anchored to the catechol groups of the dopamine methacrylamide.
  • the antibacterial agent is not easily washed away by tears, thereby allowing the ophthalmic lens to maintain an antibacterial effect.
  • the antibacterial solution comprises metal ions (such as silver ions) functioning as the antibacterial agent
  • the catechol groups are able to reduce the metal ions to be nano metal particles which are anchored to the catechol groups.
  • the antibacterial agent comprises thiol groups or amine groups functioning as the antibacterial agent
  • the catechol groups react with the thiol groups or the amine groups to form covalent bonds, thereby anchoring the antibacterial agent to the dopamine methacrylamide.
  • the block 103 can be omitted from the method for making an ophthalmic lens, and such a step can be performed before wearing the ophthalmic lens.
  • a mixture is formed by mixing dopamine methacrylamide, 2-hydroxyethyl methacrylate, poly(dimethylsiloxane), ethylene glycol dimethacrylate, and Irgacure-1173.
  • the dopamine methacrylamide has a mass percentage of 1% of a total mass of the mixture.
  • the 2-hydroxyethyl methacrylate has a mass percentage of 60% of a total mass of the mixture.
  • the poly(dimethylsiloxane) has a mass percentage of 38.94% of a total mass of the mixture.
  • the ethylene glycol dimethacrylate has a mass percentage of 0.05% of a total mass of the mixture.
  • Irgacure-1173 has a mass percentage of 0.01% of a total mass of the mixture.
  • the mixture is fed into a mold and is exposed to ultraviolet radiation for 25 min, thereby forming an ophthalmic lens.
  • a mixture is formed by mixing dopamine methacrylamide, 2-hydroxyethyl methacrylate, 3-methacryloxypropyletris (trimethylsiloxy) silane, ethylene glycol dimethacrylate, and Irgacure-1173.
  • the dopamine methacrylamide has a mass percentage of 10% of a total mass of the mixture.
  • the 2-hydroxyethyl methacrylate has a mass percentage of 45% of a total mass of the mixture.
  • the 3-methacryloxypropyletris (trimethylsiloxy) silane has a mass percentage of 43.98% of a total mass of the mixture.
  • the ethylene glycol dimethacrylate has a mass percentage of 1% of a total mass of the mixture.
  • Irgacure-1173 has a mass percentage of 0.02% of a total mass of the mixture.
  • the mixture is fed into a mold and is exposed to ultraviolet radiation for 30 min, thereby forming an ophthalmic lens.
  • a mixture was formed by mixing dopamine methacrylamide, methyl methacrylate, 3-methacryloxypropyletris (trimethylsiloxy) silane, ethylene glycol dimethacrylate, and Irgacure-1173.
  • the dopamine methacrylamide has a mass percentage of 5% of a total mass of the mixture.
  • the methyl methacrylate has a mass percentage of 30% of a total mass of the mixture.
  • the 3-methacryloxypropyletris (trimethylsiloxy) silane has a mass percentage of 64.94% of a total mass of the mixture.
  • the ethylene glycol dimethacrylate has a mass percentage of 0.05% of a total mass of the mixture.
  • Irgacure-1173 has a mass percentage of 0.01% of a total mass of the mixture. The mixture was fed into a mold and was exposed to ultraviolet radiation for 28 min, thereby forming an ophthalmic lens.
  • the ophthalmic lens obtained from the example 1 was immersed in a silver nitrate solution having a concentration of 1 mmol/L for 12 hours, thereby causing silver nano particles to be anchored to the catechol groups of the dopamine methacrylamide comprised in the ophthalmic lens.
  • the ophthalmic lens obtained from the example 2 was immersed in a silver nitrate solution having a concentration of 15 mmol/L for 16 hours, thereby causing silver nano particles to be anchored to the catechol groups of the dopamine methacrylamide comprised in the ophthalmic lens.
  • the ophthalmic lens obtained from the example 3 was immersed in a antibacterial peptide solution for 20 hours, thereby causing antibacterial peptides comprised in the antibacterial peptide solution to be anchored to the catechol groups of the dopamine methacrylamide comprised in the ophthalmic lens.
  • the ophthalmic lens material comprises dopamine methacrylamide, a hydrophilic monomer, a cross-linking agent, and a photoinitiator.
  • the dopamine methacrylamide has a mass percentage of about 0.5% to about 10% of a total mass of the ophthalmic lens material.
  • the hydrophilic monomer has a mass percentage of about 88.95% to about 99.494% of a total mass of the ophthalmic lens material.
  • the cross-linking agent has a mass percentage of about 0.001% to about 1% of a total mass of the ophthalmic lens material.
  • the photoinitiator has a mass percentage of about 0.005% to about 0.05% of a total mass of the ophthalmic lens material.
  • the dopamine methacrylamide, the hydrophilic monomer, the photoinitiator, and the cross-linking agent undergo a polymerization reaction, thereby forming an ophthalmic lens.
  • An ophthalmic lens made by the method is provided according the present disclosure.
  • the ophthalmic lens is formed by exposing a mixture of the dopamine methacrylamide, the hydrophilic monomer, the photoinitiator, and the cross-linking agent to ultraviolet radiation to cause the mixture to undergo a polymerization reaction.
  • the ophthalmic lens can be a contact lens or an intraocular lens.
  • the dopamine methacrylamide has a mass percentage of about 0.5% to about 10% of a total mass of the dopamine methacrylamide, the hydrophilic monomer, the cross-linking agent, and the photoinitiator.
  • the hydrophilic monomer has a mass percentage of about 88.95% to about 99.494% of a total mass of the dopamine methacrylamide, the hydrophilic monomer, the cross-linking agent, and the photoinitiator.
  • the cross-linking agent has a mass percentage of about 0.001% to about 1% of a total mass of the dopamine methacrylamide, the hydrophilic monomer, the cross-linking agent, and the photoinitiator.
  • the photoinitiator has a mass percentage of about 0.005% to about 0.05% of a total mass of the dopamine methacrylamide, the hydrophilic monomer, the cross-linking agent, and the photoinitiator.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • General Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Eyeglasses (AREA)
  • Materials For Medical Uses (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)

Abstract

A method for making an ophthalmic lens includes following steps of mixing dopamine methacrylamide, a hydrophilic monomer, a cross-linking agent, and a photoinitiator to form a mixture; feeding the mixture into a mold and exposing the mixture to ultraviolet radiation, to cause the dopamine methacrylamide, the hydrophilic monomer, the photoinitiator, and the cross-linking agent to undergo a polymerization reaction. The disclosure also provides an ophthalmic lens made by above method, and an ophthalmic lens material making for the ophthalmic lens.

Description

FIELD
The subject matter herein generally relates to an ophthalmic lens, a method for making the ophthalmic lens, and an ophthalmic lens material for making the ophthalmic lens.
BACKGROUND
Contact lenses are commonly worn by users to correct vision, or for cosmetic or therapeutic reasons. Usually, antibacterial agents are disposed on the surface of a contact lens, to prevent a user from suffering from eye damage such as acute red eye or microbial keratitis.
BRIEF DESCRIPTION OF THE DRAWINGS
Implementations of the present technology will now be described, by way of example only, with reference to the attached FIGURES.
The FIGURE is a flowchart of an embodiment of a method for making an ophthalmic lens according to the present disclosure.
 DETAILED DESCRIPTION
It will be appreciated that for simplicity and clarity of illustration, where appropriate, reference numerals have been repeated among the different FIGURES to indicate corresponding or analogous elements. In addition, numerous specific details are set forth in order to provide a thorough understanding of the embodiments described herein. However, it will be understood by those of ordinary skill in the art that the embodiments described herein can be practiced without these specific details. In other instances, methods, procedures, and components have not been described in detail so as not to obscure the related relevant feature being described. Also, the description is not to be considered as limiting the scope of the embodiments described herein. The drawings are not necessarily to scale and the proportions of certain parts may be exaggerated to better illustrate details and features of the present disclosure.
The term “comprising,” when utilized, means “including, but not necessarily limited to”; it specifically indicates open-ended inclusion or membership in the so-described combination, group, series and the like.
The FIGURE illustrates a flowchart of a method for making an ophthalmic lens in accordance with an exemplary embodiment. The exemplary method is provided by way of example, as there are a variety of ways to carry out the method. Each block shown in the FIGURE represents one or more processes, methods or subroutines, carried out in the exemplary method. Furthermore, the illustrated order of blocks is by example only and the order of the blocks can change. Additional blocks may be added or fewer blocks may be utilized, without departing from this disclosure. The exemplary method can begin at block 101.
At block 101, a mixture is formed by mixing dopamine methacrylamide, a hydrophilic monomer, a cross-linking agent, and a photoinitiator, wherein the dopamine methacrylamide has the chemical formula:
Figure US09709703-20170718-C00001
The dopamine methacrylamide has a mass percentage of about 0.5% to about 10% of a total mass of the mixture. The hydrophilic monomer has a mass percentage of about 88.95% to about 99.494% of a total mass of the mixture. The cross-linking agent has a mass percentage of about 0.001% to about 1% of a total mass of the mixture. The photoinitiator has a mass percentage of about 0.005% to about 0.05% of a total mass of the mixture.
The hydrophilic monomer may be selected from a group consisting of methylacrylic acid compounds and acrylic compounds, or any combination thereof, such as 2-hydroxyethyl methacrylate (HEMA), methyl methacrylate (MMA), poly(dimethylsiloxane), 3-methacryloxypropyletris(trimethylsiloxy)silane, N-vinyl pyrrolidone (NVP), glycidyl methacrylate, N,N-dimethylacrylamide, and methyl acrylate (MA), or any combination thereof.
The cross-linking agent may be selected from a group consisting of ethylene glycol dimethacrylate (EGDMA) and trimethylolpropane trimethacrylate (TMPTMA), or any combination thereof. The photoinitiator may be available commercially from Chemical Industries Basel (CIBA) Corporation as a clear liquid under the trade name “Irgacure-1173”.
At block 102, the mixture is fed into a mold and is exposed to ultraviolet radiation, to cause the dopamine methacrylamide, the hydrophilic monomer, the photoinitiator, and the cross-linking agent in the mixture to undergo a polymerization reaction, thereby forming the ophthalmic lens. A time period for the ultraviolet irradiation is from about 10 min to about 30 min.
At block 103, the ophthalmic lens is immersed in an antibacterial solution containing an antibacterial agent for a preset period of time, allowing the antibacterial agent to be anchored to the catechol groups of the dopamine methacrylamide. As such, the antibacterial agent is not easily washed away by tears, thereby allowing the ophthalmic lens to maintain an antibacterial effect. When the antibacterial solution comprises metal ions (such as silver ions) functioning as the antibacterial agent, the catechol groups are able to reduce the metal ions to be nano metal particles which are anchored to the catechol groups. When the antibacterial agent comprises thiol groups or amine groups functioning as the antibacterial agent, the catechol groups react with the thiol groups or the amine groups to form covalent bonds, thereby anchoring the antibacterial agent to the dopamine methacrylamide. In other embodiments, the block 103 can be omitted from the method for making an ophthalmic lens, and such a step can be performed before wearing the ophthalmic lens.
Example 1
A mixture is formed by mixing dopamine methacrylamide, 2-hydroxyethyl methacrylate, poly(dimethylsiloxane), ethylene glycol dimethacrylate, and Irgacure-1173. The dopamine methacrylamide has a mass percentage of 1% of a total mass of the mixture. The 2-hydroxyethyl methacrylate has a mass percentage of 60% of a total mass of the mixture. The poly(dimethylsiloxane) has a mass percentage of 38.94% of a total mass of the mixture. The ethylene glycol dimethacrylate has a mass percentage of 0.05% of a total mass of the mixture. Irgacure-1173 has a mass percentage of 0.01% of a total mass of the mixture. The mixture is fed into a mold and is exposed to ultraviolet radiation for 25 min, thereby forming an ophthalmic lens.
Example 2
A mixture is formed by mixing dopamine methacrylamide, 2-hydroxyethyl methacrylate, 3-methacryloxypropyletris (trimethylsiloxy) silane, ethylene glycol dimethacrylate, and Irgacure-1173. The dopamine methacrylamide has a mass percentage of 10% of a total mass of the mixture. The 2-hydroxyethyl methacrylate has a mass percentage of 45% of a total mass of the mixture. The 3-methacryloxypropyletris (trimethylsiloxy) silane has a mass percentage of 43.98% of a total mass of the mixture. The ethylene glycol dimethacrylate has a mass percentage of 1% of a total mass of the mixture. Irgacure-1173 has a mass percentage of 0.02% of a total mass of the mixture. The mixture is fed into a mold and is exposed to ultraviolet radiation for 30 min, thereby forming an ophthalmic lens.
Example 3
A mixture was formed by mixing dopamine methacrylamide, methyl methacrylate, 3-methacryloxypropyletris (trimethylsiloxy) silane, ethylene glycol dimethacrylate, and Irgacure-1173. The dopamine methacrylamide has a mass percentage of 5% of a total mass of the mixture. The methyl methacrylate has a mass percentage of 30% of a total mass of the mixture. The 3-methacryloxypropyletris (trimethylsiloxy) silane has a mass percentage of 64.94% of a total mass of the mixture. The ethylene glycol dimethacrylate has a mass percentage of 0.05% of a total mass of the mixture. Irgacure-1173 has a mass percentage of 0.01% of a total mass of the mixture. The mixture was fed into a mold and was exposed to ultraviolet radiation for 28 min, thereby forming an ophthalmic lens.
Example 4
The ophthalmic lens obtained from the example 1 was immersed in a silver nitrate solution having a concentration of 1 mmol/L for 12 hours, thereby causing silver nano particles to be anchored to the catechol groups of the dopamine methacrylamide comprised in the ophthalmic lens.
Example 5
The ophthalmic lens obtained from the example 2 was immersed in a silver nitrate solution having a concentration of 15 mmol/L for 16 hours, thereby causing silver nano particles to be anchored to the catechol groups of the dopamine methacrylamide comprised in the ophthalmic lens.
Example 6
The ophthalmic lens obtained from the example 3 was immersed in a antibacterial peptide solution for 20 hours, thereby causing antibacterial peptides comprised in the antibacterial peptide solution to be anchored to the catechol groups of the dopamine methacrylamide comprised in the ophthalmic lens.
An ophthalmic lens material used in the method to make the ophthalmic lens is provided according the present disclosure. The ophthalmic lens material comprises dopamine methacrylamide, a hydrophilic monomer, a cross-linking agent, and a photoinitiator. The dopamine methacrylamide has a mass percentage of about 0.5% to about 10% of a total mass of the ophthalmic lens material. The hydrophilic monomer has a mass percentage of about 88.95% to about 99.494% of a total mass of the ophthalmic lens material. The cross-linking agent has a mass percentage of about 0.001% to about 1% of a total mass of the ophthalmic lens material. The photoinitiator has a mass percentage of about 0.005% to about 0.05% of a total mass of the ophthalmic lens material. When the ophthalmic lens material is exposed to ultraviolet radiation, the dopamine methacrylamide, the hydrophilic monomer, the photoinitiator, and the cross-linking agent undergo a polymerization reaction, thereby forming an ophthalmic lens.
An ophthalmic lens made by the method is provided according the present disclosure. The ophthalmic lens is formed by exposing a mixture of the dopamine methacrylamide, the hydrophilic monomer, the photoinitiator, and the cross-linking agent to ultraviolet radiation to cause the mixture to undergo a polymerization reaction. The ophthalmic lens can be a contact lens or an intraocular lens. The dopamine methacrylamide has a mass percentage of about 0.5% to about 10% of a total mass of the dopamine methacrylamide, the hydrophilic monomer, the cross-linking agent, and the photoinitiator. The hydrophilic monomer has a mass percentage of about 88.95% to about 99.494% of a total mass of the dopamine methacrylamide, the hydrophilic monomer, the cross-linking agent, and the photoinitiator. The cross-linking agent has a mass percentage of about 0.001% to about 1% of a total mass of the dopamine methacrylamide, the hydrophilic monomer, the cross-linking agent, and the photoinitiator. The photoinitiator has a mass percentage of about 0.005% to about 0.05% of a total mass of the dopamine methacrylamide, the hydrophilic monomer, the cross-linking agent, and the photoinitiator.
It is to be understood, even though information and advantages of the present embodiments have been set forth in the foregoing description, together with details of the structures and functions of the present embodiments, the disclosure is illustrative only; changes may be made in detail, especially in matters of shape, size, and arrangement of parts within the principles of the present embodiments to the full extent indicated by the plain meaning of the terms in which the appended claims are expressed.

Claims (4)

What is claimed is:
1. A method for making an ophthalmic lens comprising:
mixing dopamine methacrylamide, a hydrophilic monomer, a cross-linking agent, and a photoinitiator to form a mixture; and
feeding the mixture into a mold and exposing the mixture to ultraviolet radiation, thereby causing the dopamine methacrylamide, the hydrophilic monomer, the photoinitiator, and the cross-linking agent to undergo a polymerization reaction;
wherein the dopamine methacrylamide has a mass percentage of 0.5% to 10% of a total mass of the mixture; the hydrophilic monomer has a mass percentage of 88.95% to 99.494% of the total mass of the mixture; the cross-linking agent has a mass percentage of 0.001% to 1% of the total mass of the mixture; the photoinitiator has a mass percentage of 0.005% to 0.05% of the total mass of the mixture.
2. The method of claim 1, wherein the hydrophilic monomer is selected from a group consisting of methylacrylic acid compounds and acrylic compounds, and any combination thereof.
3. The method of claim 1, wherein the hydrophilic monomer is selected from a group consisting of 2-hydroxyethyl methacrylate, methyl methacrylate, poly(dimethylsiloxane), 3-methacryloxypropyletris(trimethylsiloxy)silane, N-vinyl pyrrolidone, glycidyl methacrylate, N,N-dimethylacrylamide, and methyl acrylate, and any combination thereof.
4. The method of claim 1, further comprising:
immersing the ophthalmic lens in an antibacterial solution containing an antibacterial agent for a preset period of time, to cause the antibacterial agent to be anchored to catechol groups of the dopamine methacrylamide.
US14/941,083 2015-11-03 2015-11-13 Ophthalmic lens material, ophthalmic lens, and method for making the same Expired - Fee Related US9709703B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US15/429,187 US9804298B2 (en) 2015-11-03 2017-02-10 Ophthalmic lens material

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
TW104136236A 2015-11-03
TW104136236 2015-11-03
TW104136236A TW201716449A (en) 2015-11-03 2015-11-03 Eye lens material, eye lens, and method for making the same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US15/429,187 Division US9804298B2 (en) 2015-11-03 2017-02-10 Ophthalmic lens material

Publications (2)

Publication Number Publication Date
US20170123106A1 US20170123106A1 (en) 2017-05-04
US9709703B2 true US9709703B2 (en) 2017-07-18

Family

ID=58634478

Family Applications (2)

Application Number Title Priority Date Filing Date
US14/941,083 Expired - Fee Related US9709703B2 (en) 2015-11-03 2015-11-13 Ophthalmic lens material, ophthalmic lens, and method for making the same
US15/429,187 Expired - Fee Related US9804298B2 (en) 2015-11-03 2017-02-10 Ophthalmic lens material

Family Applications After (1)

Application Number Title Priority Date Filing Date
US15/429,187 Expired - Fee Related US9804298B2 (en) 2015-11-03 2017-02-10 Ophthalmic lens material

Country Status (3)

Country Link
US (2) US9709703B2 (en)
IN (1) IN201614020100A (en)
TW (1) TW201716449A (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180171207A1 (en) 2015-06-17 2018-06-21 Clariant International Ltd. Water-Soluble Or Water-Swellable Polymers As Water Loss Reducers In Cement Slurries
US10513641B2 (en) * 2015-06-30 2019-12-24 Purdue Research Foundation Adhesives and methods of making the same
ES2867526T3 (en) 2016-12-12 2021-10-20 Clariant Int Ltd Use of a bio-derived polymer in a cosmetic, dermatological or pharmaceutical composition
US11384186B2 (en) 2016-12-12 2022-07-12 Clariant International Ltd Polymer comprising certain level of bio-based carbon
EP3554643B1 (en) 2016-12-15 2025-03-19 Clariant International Ltd Water-soluble and/or water-swellable hybrid polymer
US11339241B2 (en) 2016-12-15 2022-05-24 Clariant International Ltd. Water-soluble and/or water-swellable hybrid polymer
EP3554644B1 (en) 2016-12-15 2025-03-19 Clariant International Ltd Water-soluble and/or water-swellable hybrid polymer
ES3017507T3 (en) 2016-12-15 2025-05-13 Clariant Int Ltd Water-soluble and/or water-swellable hybrid polymer
TW201903017A (en) * 2017-05-31 2019-01-16 鴻海精密工業股份有限公司 Ophthalmic lens and preparation method thereof
US11130886B2 (en) * 2017-12-31 2021-09-28 Purdue Research Foundation Adhesives
AU2017445170B2 (en) * 2017-12-31 2022-03-24 Purdue Research Foundation Adhesives
WO2019190402A1 (en) * 2018-03-28 2019-10-03 Singapore Health Services Pte Ltd Biocompatible ophthalmic device
GR1010095B (en) * 2020-06-11 2021-10-08 Πανεπιστημιο Ιωαννινων Ειδικος Λογαριασμος Κονδυλιων Ερευνας, New hydrogels for the development of sterile contact lenses
JP2022133971A (en) * 2021-03-02 2022-09-14 三井化学株式会社 Antimicrobial material
CN113667094B (en) * 2021-08-31 2023-03-03 万华化学（宁波）有限公司 Exposure-resistant isocyanate composition, preparation method and application thereof in preparation of high-strength polyurethane optical resin

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100081772A1 (en) * 2008-09-30 2010-04-01 Diana Zanini Process for forming silicone hydrogel articles having improved optical properties
US20130168617A1 (en) * 2011-12-23 2013-07-04 Johnson & Johnson Vision Care, Inc. Ionic silicone hydrogels
US20140377327A1 (en) * 2013-06-20 2014-12-25 Mercy Medical Research Institute Extended release drug-delivery contact lenses and methods of making

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100081772A1 (en) * 2008-09-30 2010-04-01 Diana Zanini Process for forming silicone hydrogel articles having improved optical properties
US20130168617A1 (en) * 2011-12-23 2013-07-04 Johnson & Johnson Vision Care, Inc. Ionic silicone hydrogels
US20140377327A1 (en) * 2013-06-20 2014-12-25 Mercy Medical Research Institute Extended release drug-delivery contact lenses and methods of making

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Chung et al, Enhanced Adhesion of Dopamine Methacrylamide Elastomers via Viscoelasticity Tuning, Dec. 23, 2010, Biomacromolecules, 12, 342-347. *

Also Published As

Publication number Publication date
US9804298B2 (en) 2017-10-31
TW201716449A (en) 2017-05-16
US20170153360A1 (en) 2017-06-01
US20170123106A1 (en) 2017-05-04
IN201614020100A (en) 2017-05-05

Similar Documents

Publication Publication Date Title
US9709703B2 (en) Ophthalmic lens material, ophthalmic lens, and method for making the same
US20170123229A1 (en) Method for making a colorant film, colorant film, and ophthalmic lens
RU2639785C2 (en) Method and apparatus for hard insert encapsulation into contact lens for vision adjustment in patients with astigmatism
TWI512017B (en) Wettable silicone hydrogel contact lenses and related compositions and methods
EP2087382A2 (en) Process for forming clear, wettable silicone hydrogel articles
KR20090091297A (en) Methods of Forming Transparent, Wettable Silicone Hydrogel Products
EP1763547B1 (en) Silicone hydrogels with lathability at room temperature
CN103848946A (en) Silica gel composition and silica gel lens prepared from same
US10143203B2 (en) Antibacterial spectacle part and antibacterial treatment method
KR20110014672A (en) Silicone Hydrogel Contact Lenses Showing Reduced Protein Absorption
TW200821120A (en) Excess polymer ring removal during ophthalmic lens manufacture
JPS62240517A (en) Method and device for stacking casting molding of article
EP3251757A1 (en) Method for manufacturing plastic lens having coating layer
TWI820002B (en) Increased stiffness center optic in soft contact lenses for astigmatism correction
RU2681222C2 (en) Polymers comprising sulfonic acid groups
TWI788924B (en) Surface-modified contact lens, method of preparing the same, and method of modifying surface of polymeric material
US9896531B2 (en) Formulation for silicone hydrogel, silicone hydrogel and method for forming silicone hydrogel
US20160046801A1 (en) Silicone hydrogel contact lens and method for manufacturing the same
US20180250899A1 (en) Contact lens and method for making the same
US20190015022A1 (en) Contact lens for detecting glucose level in tears and method for making the same
JP3133197B2 (en) Method for manufacturing transparent optical resin molded products
US20180230257A1 (en) Ophthalmic lens and method for making the same
US20170112888A1 (en) Eye lens and method for making same
CN104924508B (en) For the manufacture method of the mould of contact lenses, method for sorting and contact lenses
TW202509586A (en) Method of producing a hybrid contact lens having a hydrophobic member inside

Legal Events

Date Code Title Description
AS Assignment

Owner name: HON HAI PRECISION INDUSTRY CO., LTD., TAIWAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CHIEN, HSIU-WEN;REEL/FRAME:037038/0322

Effective date: 20151109

STCF Information on status: patent grant

Free format text: PATENTED CASE

FEPP Fee payment procedure

Free format text: MAINTENANCE FEE REMINDER MAILED (ORIGINAL EVENT CODE: REM.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

LAPS Lapse for failure to pay maintenance fees

Free format text: PATENT EXPIRED FOR FAILURE TO PAY MAINTENANCE FEES (ORIGINAL EVENT CODE: EXP.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362

FP Lapsed due to failure to pay maintenance fee

Effective date: 20210718